Format

Send to

Choose Destination
Lancet. 2016 Dec 10;388(10062):2895-2903. doi: 10.1016/S0140-6736(16)32049-9. Epub 2016 Dec 1.

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.

Author information

1
School of Medicine, University of California San Francisco, San Francisco, CA, USA; Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA. Electronic address: john.teerlink@ucsf.edu.
2
Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
3
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
4
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
5
Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
6
National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
7
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
8
Department of Cardiology, Queen Giovanna University Hospital and Medical University-Sofia, Sofia, Bulgaria.
9
Heart Transplant Unit, St Vincent's Hospital and Transplantation Research Laboratory, Victor Chang Cardiac Research Institute and University of New South Wales, Sydney, NSW, Australia.
10
Division of Cardiology, University of Brescia, Brescia, Italy.
11
Kerckhoff-Klinik Forschungsgesellschaft, Frankfurt, Germany; Johann-Wolfgang Goethe University, Main, Germany.
12
Department of Heart Diseases, Medical University and Centre for Heart Diseases, Military Hospital, Wrocław, Poland.
13
Emergency Centre, Vilnius University Hospital Santariskiu Klinikos and Vilnius University, Vilnius, Lithuania.
14
University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.
15
Cardiology Department, St John of God Hospital, Budapest, Hungary.
16
Department of Cardiology, AZ-St-Lucas, Ghent, Belgium.
17
University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
18
Amgen, Thousand Oaks, CA, USA.
19
Cytokinetics, South San Francisco, CA, USA.

Abstract

BACKGROUND:

Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil.

METHODS:

In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512.

FINDINGS:

From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean differences were as follows: systolic ejection time 25 ms (95% CI 18-32, p<0·0001), stroke volume 3·6 mL (0·5-6·7, p=0·0217), left ventricular end-systolic diameter -1·8 mm (-2·9 to -0·6, p=0·0027), left ventricular end-diastolic diameter -1·3 mm, (-2·3 to 0·3, p=0·0128), heart rate -3·0 beats per min (-5·1 to -0·8, p=0·0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0·0069). The frequency of adverse clinical events did not differ between groups.

INTERPRETATION:

Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter.

FUNDING:

Amgen.

PMID:
27914656
DOI:
10.1016/S0140-6736(16)32049-9
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center